Safety and pharmacokinetics of oral lansoprazole in preadolescent rats exposed from weaning through sexual maturity

Reproductive Toxicology

Volumn 17, Issue 1, 2003, Pages 109-116

  Youssef, Ashraf F ^a   Turck, Pat ^b   Fort, Farrel L ^a  

^a TAP PHARMACEUTICAL PRODUCTS INC   (United States)

^b MPI RESEARCH   (United States)

Author keywords

Animal model; Lansoprazole; Neurobehavioral; Pharmacokinetics; Preadolescent; Rats

Indexed keywords

ALBUMIN; LANSOPRAZOLE; PROTEIN; PROTON PUMP INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; COGNITION; CONTROLLED STUDY; DEVELOPMENTAL STAGE; DOSE RESPONSE; DRUG SAFETY; DUODENUM; EXPOSURE; FEMALE; HISTOPATHOLOGY; HYPOGLYCEMIA; IRON DEFICIENCY ANEMIA; LIVER WEIGHT; MALE; NEWBORN; NONHUMAN; OPHTHALMOLOGY; ORGAN WEIGHT; RAT; SEXUAL MATURATION; SEXUAL MATURITY; SPLEEN; STOMACH; THYMUS; TOXICITY; URINALYSIS; WEANING;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADMINISTRATION, ORAL; ANEMIA, HYPOCHROMIC; ANIMALS; ANTI-ULCER AGENTS; AREA UNDER CURVE; BEHAVIOR, ANIMAL; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HYPOGLYCEMIA; MODELS, ANIMAL; NO-OBSERVED-ADVERSE-EFFECT LEVEL; OMEPRAZOLE; ORGAN SIZE; RATS; RATS, WISTAR; SERUM ALBUMIN; SEXUAL MATURATION; WEANING;

ANIMALIA;

EID: 0242586086     PISSN: 08906238     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0890-6238(02)00099-0     Document Type: Article

References (38)

1. Satoh H, Inatomi N, Nagaya H, Inada I, Nohara A, Nakamura N, et al. Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats. J Pharmacol Exp Ther 1989;248:806-15.
2. Barradell LB, Faulds D, Mctavish D. Lansoprazole: a review of its pharmacodynamic and phannacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs 1992;44:225-50.
3. Klassen C. Toxicology, the basic science of poisons; 1996, p. 144. New York: McGraw-Hill.
4. Arimori K, Yasuda K, Katsuki H, Nakano M. Pharmacokinetics differences between lansoprazole enetiomers in rats. J Pharm Pharmacol 1998;50:1241-5.
5. Faure C, Pelaran C, Languepin J. Inhibiteurs de la pompe à protons en pédiatrie. Arch Pédiatr 1999;6:650-6 (English summary).
6. Prevacid, http://www.pdrel.com/pdr/static.htm?path=pdrel/pdr/8100 1000.htm, 7/1/2002.
7. Freston JW, Rose PA, Heller CA, Haber M, Jennings D. Safety profile of lansoprazole: the US clinical trial experience. Drug Safety 1999;20:195-205.
8. Reilly JP. Safety profile of the proton-pump inhibitors. Am J Health Syst Pharm 1999;56(23 Suppl 4):S11-7.
9. Leufkens H, Claessens A, Heerdink E, van Eijk J, Lamers CB. A prospective follow-up study of 5669 users of lansoprazole in daily practice. Aliment Pharmacol 1997;11(5):887-97.
10. Tran A, Rey D, Pons G, Pariente-Khayat A, d'Athis P, Sallerin V, et al. Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. Clinical Pharm Ther 2002;71(5):359-67.
11. Tolia V, Brown W, El-Baba M, Lin C. Helicobacter pylori culture and antimicrobial susceptibility from pediatric patients in Michigan. Pediatr Infect Dis J 2000;19(12):1167-71.
12. Franco MT, Salvia G, Terrin G, Spadaro R, De Rosa I, Iula VD, et al. Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood. Dig Liver Dis 2000;32(8):660-6.
13. Shashidhar H, Peters J, Lin CH, Rabah R, Thomas R, Tolia V. A prospective trial of lansoprazole triple therapy for pediatric Helicobacter pylori infection. J Pediatr Gastroenterol Nutr 2000;30(3):276-82.
14. Faure C, Michaud L, Khan Shaghaghi E, Popon M, Laurence M, Mougenot JF, et al. Lansoprazol in children: pharmacokinetics and efficacy in reflux oesphagitis. Aliment Pharmacol Ther 2001;15:1397-402.
15. International Conference on Harmonization E11: Clinical Investigation of Medicinal Products in Pediatric Population. http://www. fda.gov/OHRMS/DOCKETS/98fr/041200c.txt. 7/17/02.
16. US Department of Health and Human Services. Guide for the Care and Use of Laboratory Animals; 1996
17. US Food and Drug Administration. Department of Health and Human Services. Good Laboratory Practice Regulations; Final Rule (21 CFR Part 58); 1987.
18. Welch BL. The significance of difference between two means when variances are unequal. Biometrika 1937;29:350-62.
19. Keith R, et al. A study to evaluate the effects of lansoprazole in pediatric subjects with esophagitis treated for eight to twelve weeks lansoprazole data on file (Unpublished), TAP Pharmaceutical Products, Inc. Lake Forest, IL; 2001.
20. Atkinson JE, Daly JW. A three-month oral gavage range-finding study of AG-1749 in rats. Data on File (Unpublished) TAP Pharmaceutical Products, Inc. Lake Forest, IL; 1986.
21. Miyajima H. Thirteen-week, oral toxicity study of AG-1749 in rats. Data on File (Unpublished). TAP Pharmaceutical Products, Inc. Lake Forest, IL; 1986.
22. +-ATPase inhibitor, on duodenal ulcerogenic and heating responses in rats: a comparative study with omeprazole and lansoprazole. J Gastroenterol Hepatol 1999;14:251-7.
23. Rodrigues D. Hepatic drug metabolizing activity in mice and rats after 14 days of oral treatment with lansoprazole. Data on File (Unpublished), TAP Pharmaceutical Products, Inc., Lake Forest, IL; 1993.
24. Rich KJ, Boobis AR, Expression and inducibility of P450 enzymes during liver ontogeny. Microsc Res Tech 1997;39:424-35.
25. Atlas SA, Boobis AR. Felton JS, Thorgeirsson SS, Nebert DW. Ontogenetic expression of polycyclic aromatic compound-inducible monooxygenase activities and forms of cytochrome P-450 in rabbit. Evidence for temporal control and organ specificity of two genetic regulatory systems. J Biol Chem 1977;252:4712-21.
26. Thorgeirsson SS, Atlas SA, Boobis AR, Felton JS. Species differences in the substrate specificity of hepatic cytochrome P-448 from polycyclic hydrocarbon-treated animals. Biochem Pharmacol 1979;28:217-26.
27. Sonnier M, Cresteil T. Delayed ontogenesis of CYP1A2 in the human liver. Eur J Biochem 1998;215:893-8.
28. Kobayashi T. Metabolic fate of AG-1749 in rats: dose-dependency. Report No. A-29-625. Data on File (Unpublished), TAP Pharmaceutical Products, Inc., Lake Forest, IL; 1990.
29. Masubuchi N, Okazaki O. An envaluation of the CYP1A induction potential of pantoprazole in primary rat hepatocytes: a comparison with other proton pump inhibitors. Chem Biol Interact 1997;107:63-74.
30. Masubuchi N, Hakusui H, Okazaki O. Effects of pantoprazole on xenobiotics metabolizing enzymes in rat liver microsomes: a comparison with other proton pump inhibitors. Drug Metab Dispos 1997;25:584-9.
31. Ginsberg G, Hattis D, Sonawane B, Russ A, Banati P, Kozlak M, et al. Evaluation of child/adult pharmacokinetics differences from a database derived from the therapeutic drug literature. Toxicol Sci 2002;66(2):185-200.
32. Majors K. Two-year oral oncogenicity study in rats of Lansoprazole. IRDC. Data on File (Unpublished), TAP Pharmaceutical Products, Inc. Lake Forest, IL; 1993.
33. Miyajima H. Study 1148/CA: A twenty-four month oral oncogenicity study of AG-1749 in Rats. Data on File (Unpublished), TAP Pharmaceutical Products, Inc., Lake Forest, IL; 1993.
34. Kedderis GL, Mugford CA. Sex-dependent metabolism of xenobiotics. CIIT 1998;18(7/8):1-8.
35. Selort CR, Kinden DA, Stjth R. Fetal and neonatal development of the microsomal monooxygenase system. Drug Metab Rev 1976;5(1):1-42.
36. Shih H, Pickwell GV, Guenett DK, Bilir B, Quattrochi LC. Species differences in hepatocyte induction of CYP1A1 and CYPIA2 by omeprazole. Hum Exp Toxicol 1999;18:95-105.
37. Derelanko MJ. CRC Handbook of Toxicology. New York: CRC Press; 1995, p. 647.
38. Vernier VG, Alleva FR. The bioassay of kanamycin auditory toxicity. Arch Int Pharmacodyn 1968;1176:59-73.